Elad Sharon

Research interests

Publications

• Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults

  New England Journal of Medicine · 2024 · 10.1056/nejmoa2312948

• Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

  New England Journal of Medicine · 2024 · 10.1056/nejmoa2401726

• Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2211437

• Atezolizumab for Advanced Alveolar Soft Part Sarcoma

  New England Journal of Medicine · 2023 · 10.1056/nejmoa2303383

• Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

  Nature Medicine · 2023 · 10.1038/s41591-023-02498-y

• Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology

  Journal for ImmunoTherapy of Cancer · 2023 · 10.1136/jitc-2022-006398

• Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

  The Lancet Oncology · 2022 · 10.1016/s1470-2045(21)00658-6

• Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia

  JAMA · 2021 · 10.1001/jama.2021.0669

• Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

  Journal for ImmunoTherapy of Cancer · 2021 · 10.1136/jitc-2021-002990

• A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

  Clinical Cancer Research · 2020 · https://doi.org/10.1158/1078-0432.ccr-19-3356

• Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

  Journal for ImmunoTherapy of Cancer · 2020 · 10.1136/jitc-2019-000398

• Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q

  Annals of Oncology · 2019 · 10.1093/annonc/mdz291

• Current Landscape of Immunotherapy in Breast Cancer

  JAMA Oncology · 2019 · 10.1001/jamaoncol.2018.7147

• Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy

  Journal of Clinical Oncology · 2019 · 10.1200/jco.18.01896

• Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study

  JAMA Oncology · 2019 · 10.1001/jamaoncol.2019.2244

• Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study

  Journal of Clinical Oncology · 2019 · 10.1200/jco.19.01056

• Tuberculosis following PD-1 blockade for cancer immunotherapy

  Science Translational Medicine · 2019 · 10.1126/scitranslmed.aat2702

• Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

  Journal of Clinical Oncology · 2019 · 10.1200/jco.19.01674

• Nivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1D—A Subprotocol of the NCI-MATCH (EAY131) Study

  Journal of Clinical Oncology · 2019 · 10.1200/jco.19.00818

• Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity

  Clinical Cancer Research · 2017 · 10.1158/1078-0432.ccr-16-3065

• PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

  New England Journal of Medicine · 2016 · 10.1056/nejmoa1603702

• Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125

  Cancer · 2014 · 10.1002/cncr.28875

• IGF-1R as an anti-cancer target--trials and tribulations

  癌症：英文版 · 2013 · 10.5732/cjc.012.10263

• Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression

  Science Translational Medicine · 2013 · 10.1126/scitranslmed.3006941

• Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers

  Clinical Cancer Research · 2010 · 10.1158/1078-0432.ccr-10-2275

Current projects

No projects listed.